SPECIAL NOTICE
A -- Identification, Referral & Followup of Patients who have HTLV
- Notice Date
- 6/11/2012
- Notice Type
- Special Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- N01RC-2008-00011
- Archive Date
- 7/14/2012
- Point of Contact
- Charlotte L. McCormack, Phone: 3014353757, Lisa Hill, Phone: 301-496-6987
- E-Mail Address
-
mccormackc@mail.nih.gov, hilll1@nih.gov
(mccormackc@mail.nih.gov, hilll1@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The Department of Health and Human Services, National Institutes of Health, at the National Cancer Institute, the Metabolism Branch, and Office of Acquisitions intends to negotiate a sole source modification for a six month extension to the contract with the West Indies University in Mona, Jamaica to continue follow-up for patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma (ATL). Since 1997 the Metabolism Branch has established a "piggyback" to contracts held by the Viral Epidemiology Branch with West Indies University for NCI contract numbers NO1-CP-40548 (1994-2001) and NO1-CP-21121(2001-2006). Through these contracts NCI has evaluated and treated many ATL patients. VEB terminated their contracts in this area on July 1, 2006. Following the contract, the Metabolism Branch, NCI established two purchase orders to continue to locate, treat and evaluate and follow the ATL patients. The purchase orders ended July 1, 2008 when a new contract HHSN26120080011C was established. Statutory authority: 41 U.S.C. 253(c)(1), as set forth in FAR 6.302-1(a)(2)(ii), only one responsible source and no other supplies or services will satisfy agency requirements. West Indies University is the only responsible source and no other supplies or services will satisfy agency requirements. The etiology of HTLV-1 ATL is such that the human populations that carry this disease exist primarily in the Caribbean basin. Therefore, offerors must provide sufficient information that they can recruit, treat, and follow patients who reside in the West Indies. This includes patients currently on NCI Protocols at the time of the award of the contract. The West Indies is the primary etiological source of patients who suffer from Adult-T-Cell leukemia. The proposed project will be a continuation of ongoing studies of patients with HTLV-1 positive with Adult T-Cell Leukemia (ATL). The University of West Indies is uniquely qualified by virtue of its continued performance for this period of time and is the only source that can provide services at this time. The purpose of extending this contract is to complete the following active studies: 1) Identify members of the patient population who meet the criteria specified by the Clinical Trials Protocols that the Metabolism Branch, National Cancer Institute (NCI) will provide.. 2) Interact with the staff at the NCI, assist staff and patients with compliance of the clinical protocols for treatment of the patients at the National Institute of Health (NIH) Clinical Center in Bethesda, MD (USA) and then follow-up when the patients have returned to their home country. Perform patient diagnoses, pre-referral evaluations including laboratory data, post-referral evaluations, and provide blocks and slides of tissues to the NCI. 3) Assist patients in obtaining VISAs, passports and other documentation required for travel to the Washington DC area airports, and to the NCI from their home country. 4) Interact with the NCI staff electronically concerning patient issues. 5) Comply with the US Food and Drug Administration (USDA) regulations concerning Investigational New Drugs, adhere to all regulations of the NIH Clinical Center in Bethesda, MD (USA). 6) Adhere to any regulatory agency requirements in the Contractor's geographical location. As part of the work under this potential contract semi-annual and final technical report are expected. The proposed contract action is for supplies or services for which the Government intends to continue with one source under authority FAR 6.302. However, interested sources may identify their interest and capability must respond by submitting a capability statement (5 page limit) within 15 days of publication of this synopsis. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. The capability statement will be considered solely for the purpose of determining whether to conduct a competitive procurement. Overnight deliveries should be mailed to Charlotte McCormack at the National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, Suite 600, Bethesda, Maryland 20852. No collect calls or facsimile transmissions will be accepted. Respondents may submit their capability statements via email at mccormackc@mail.nih.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N01RC-2008-00011/listing.html)
- Record
- SN02772567-W 20120613/120611235640-00d2619e9ba50ab44d02b411980b74b7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |